Drug
Budoprutug
Budoprutug is a pharmaceutical drug with 6 clinical trials. Currently 4 active trials ongoing. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
4(67%)
Results Posted
0%(0 trials)
Phase Distribution
Ph early_phase_1
1
17%
Ph phase_2
1
17%
Ph phase_1
4
67%
Phase Distribution
5
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
1(16.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
4
trials recruiting
Total Trials
6
all time
Status Distribution
Active(4)
Completed(1)
Terminated(1)
Detailed Status
Recruiting4
Completed1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
4
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Early Phase 11 (16.7%)
Phase 14 (66.7%)
Phase 21 (16.7%)
Trials by Status
completed117%
recruiting467%
withdrawn117%
Recent Activity
4 active trials
Showing 5 of 6
recruitingphase_1
A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
NCT07564596
completedearly_phase_1
A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers
NCT07090655
recruitingphase_2
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
NCT07096843
recruitingphase_1
A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
NCT07011043
recruitingphase_1
A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
NCT07043946
Clinical Trials (6)
Showing 6 of 6 trials
NCT07564596Phase 1
A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
NCT07090655Early Phase 1
A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers
NCT07096843Phase 2
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
NCT07011043Phase 1
A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
NCT07043946Phase 1
A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
NCT06570434Phase 1
Phase 1b/2a in SLE With Budoputug
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6